Further development is expected to yield second-generation PROTACs combining superior ex vivo activities (inhibition of CDK6-regulated S phase; CDK6 degradation) with improved pharmacokinetic properties that might establish these drugs as bona fide anti-cancer therapeutics. Here, CDK6 is linked to cancer.